Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 18 years of age at time of screening~* Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization~* Moderate to severe psoriasis as defined at baseline by:~  * PASI score of 12 or greater~ * Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and,~ * Body Surface Area affected by plaque-type psoriasis of 10% or greater~* Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator.~Exclusion Criteria:~* Forms of psoriasis other than chronic plaque-type~* Drug-induced psoriasis~* Ongoing use of prohibited psoriasis treatments~* Previous exposure to adalimumab~* Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with adalimumab~Other In-/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP2017 Adalimumab (Type: EXPERIMENTAL): Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
- Humira ® Adalimumab (Type: ACTIVE_COMPARATOR): Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.

Based on this trial design, predict the completion outcome and termination type (if applicable).